Medulloblastoma genes as targets for diagnosis and therapeutics
Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis.
1. A method of testing a medulloblastoma tumor, comprising:
testing a gene or its encoded mRNA, cDNA, or protein in a sample of the medulloblastoma tumor and detecting in the gene or its encoded mRNA, cDNA, or protein in the sample of the medulloblastoma tumor a somatic mutation in genes MLL2 or MLL3.
2. The method of claim 1 further comprising testing a matched non-tumor sample for the mutation.
3. The method of claim 1 wherein the gene is tested.
4. The method of claim 1 wherein the cDNA is tested.
5. The method of claim 1 wherein the protein is tested.
6. The method of claim 1 wherein a mutation in gene MLL2 is detected.
7. The method of claim 1 wherein a mutation in gene MLL3 is detected.
8. The method of claim 1 wherein the step of testing comprises sequence determination of all or part of a gene or cDNA.
9. The method of claim 1 wherein the step of testing employs a mutation-specific probe or a mutation-specific primer.
10. The method of claim 1 wherein the step of testing comprises amplification of nucleic acids.
11. The method of claim 1 wherein the step of testing employs a primer extension reaction.
12. The method of claim 1 wherein the step of testing employs nucleic acid hybridization.
13. The method of claim 1 wherein the mutation is a nonsense, out-of-frame insertion, out-of-frame deletion, or splice site mutation.
14. The method of claim 1 wherein the medulloblastoma is a large cell/anaplastic medulloblastoma tumor.
15. The method of claim 1 wherein the mutation is selected from the group consisting of: c14761C>T, c14555G>A, c6941delC, c10972C>T, c7851delC, c1876_1877insG, c1652C>T, c3880_3883delGaCT, c13802G>A, c2655dupC, and c4024C>T.
16. The method of claim 1 wherein the mutation is selected from the group consisting of: P551L, G4601E, Q1342X, R4921X, R4852Q, and R3658C.
17. The method of claim 15 which employs a mutation-specific probe or primer.